Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I study of COVID-HIG for post-exposure prophylaxis in individuals at high risk of exposure to SARS-CoV-2 in healthy adults

Next Previous
Trial Profile

A Phase I study of COVID-HIG for post-exposure prophylaxis in individuals at high risk of exposure to SARS-CoV-2 in healthy adults

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 03 Jan 2021 New trial record
  • 29 Dec 2020 According to an Emergent BioSolutions media release, the company and Mount Sinai Health System has initiated the program in this trial. The U.S. Department of Defense's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) has provided funding to support this program.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top